Drug Combination Details
General Information of the Combination (ID: C46103) | |||||
---|---|---|---|---|---|
Name | Elemene NP Info | + | Cisplatin Drug Info | ||
Structure | + | ||||
Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [2] | |||
Lung cancer
[ICD-11: 2C25]
|
Investigative | [3] | |||
Gingival squamous cell carcinoma
[ICD-11: 2E90]
|
Investigative | [4] | |||
Bladder cancer
[ICD-11: 2C94]
|
Investigative | [5] | |||
Click to Show/Hide the Whole Disease Information of This Combination |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [5] | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | PRKAA2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | T24 | CVCL_0554 | Bladder carcinoma | Homo sapiens | ||
5637 | CVCL_0126 | Bladder carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Beta-elemene enhances cisplatin-induced apoptosis in bladder cancer cells through the ROS-AMPK signaling pathway. | |||||
Experiment 2 Reporting the Effect of This Combination | [3] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Beta-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway. | |||||
Experiment 3 Reporting the Effect of This Combination | [4] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | JAK-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | YD-38 | CVCL_L083 | Gingival squamous cell carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Synergistic cytotoxicity of beta-elemene and cisplatin in gingival squamous cell carcinoma by inhibition of STAT3 signaling pathwaybeta-elemene promoted the anti-proliferative and apoptotic effect of cisplatin by inhibiting STAT3 and blocking the JAK2-STAT3 signaling pathway in GSCC in vitro and in vivo. | |||||
Experiment 4 Reporting the Effect of This Combination | [6] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. | |||||
Experiment 5 Reporting the Effect of This Combination | [2] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A2780/CP | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
MCAS | CVCL_3020 | Ovarian mucinous cystadenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Beta-elemene sensitizes chemoresistant ovarian carcinoma cells to cisplatin-induced apoptosis and that the augmented effect of Beta-elemene on cisplatin cytotoxicity and sensitivity in resistant ovarian tumor cells is mediated through a mitochondria- and caspase-dependent cell death pathway. | |||||
Experiment 6 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Beta-Elemene significantly increased cisplatin anticancer effects in the androgen-independent prostate carcinoma cell lines DU145 and PC-3. | |||||
Experiment 7 Reporting the Effect of This Combination | [7] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP10 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | T24 | CVCL_0554 | Bladder carcinoma | Homo sapiens | ||
5637 | CVCL_0126 | Bladder carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Beta-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. | |||||
Experiment 8 Reporting the Effect of This Combination | [8] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | GADD45A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | IFI27 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MPIP3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Sensitization of lung cancer cells to cisplatin by Beta-elemene is mediated through blockade of cell cycle progression. | |||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [3] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
beta-ELE enhanced the sensitivity of A549/DDP cells to cisplatin and reversed the drug resistance of A549/DDP cells via the mitochondrial apoptosis pathway. | |||||
Experiment 2 Reporting the Effect of This Combination | [6] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. | |||||
Experiment 3 Reporting the Effect of This Combination | [5] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | PRKAA1 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | T24 | CVCL_0554 | Bladder carcinoma | Homo sapiens | ||
5637 | CVCL_0126 | Bladder carcinoma | Homo sapiens | |||
Experimental
Result(s) |
beta-elemene enhances cisplatin-induced apoptosis in bladder cancer cells through the ROS-AMPK signaling pathway. | |||||
Experiment 4 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Down-regulation | Cytochrome c release | ||||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
beta-elemene enhancement of cisplatin-induced apoptosis via mitochondrial activation of the caspase-mediated apoptotic pathway may account for the augmented anti-cancer potency of cisplatin in prostate cancer. | |||||
Experiment 5 Reporting the Effect of This Combination | [7] | |||||
Molecule(s)
Regulation |
Up-regulation | Activity | CASP10 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | CASP7 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | T24 | CVCL_0554 | Bladder carcinoma | Homo sapiens | ||
5637 | CVCL_0126 | Bladder carcinoma | Homo sapiens | |||
Experimental
Result(s) |
beta-elemene augments the antitumor activity of cisplatin in human bladder cancer by enhancing the induction of cellular apoptosis via a caspase-dependent mechanism. | |||||
Experiment 6 Reporting the Effect of This Combination | [8] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | GADD45A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | IFI27 | Molecule Info | |||
Down-regulation | Expression | MPIP3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression. |